Meeting
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
Authors
Weihua Guo
City of Hope National Medical Center, Duarte, CA
Weihua Guo , Colt A. Egelston , Katherine E. Hutchinson , Jennifer M. Giltnane , Veronica Ibarra-Lopez , Bonnie Liu , Susan Elaine Yost , Daniel Schmolze , Peter P. Lee , Yuan Yuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1079)
DOI
10.1200/JCO.2022.40.16_suppl.1079
Abstract #
1079
Poster Bd #
457
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Genitourinary Cancers Symposium
Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).
First Author: Laura Cattaneo
Poster
2022 ASCO Annual Meeting
Analysis of the contribution of macrophages to the overall tumor PD-L1 microenvironment using a screening multi-tumor tissue microarray and rapid multiplex fluorescence digital phenotyping approach.
First Author: Marie Cumberbatch
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi